Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - AHCYL1 |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - AHCYL1 | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-AHCYL1 were sensitive to treatment with Futibatinib (TAS-120) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - AHCYL1 | cholangiocarcinoma | predicted - sensitive | FGFR2 Inhibitor | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FIGHT-202), Pemazyre (pemigatinib) treatment in a cholangiocarcinoma patient harboring FGFR2-AHCYL1 resulted in stable disease with a decrease in tumor size of 33.3% and progression-free survival of 6.8 months (PMID: 33218975; NCT02924376). | 33218975 |
FGFR2 - AHCYL1 | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-AHCYL1 were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - AHCYL1 | Advanced Solid Tumor | sensitive | PD173074 | Preclinical | Actionable | In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810). | 24122810 | |
FGFR2 - AHCYL1 | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | AZD4547 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-AHCYL1 were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - AHCYL1 | Advanced Solid Tumor | predicted - resistant | FGFR Inhibitor (Pan) | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-AHCYL1 were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
FGFR2 - AHCYL1 | intrahepatic cholangiocarcinoma | predicted - sensitive | FGFR2 Inhibitor | Derazantinib | Case Reports/Case Series | Actionable | In a Phase Ib/II trial, a patient with intrahepatic cholangiocarcinoma harboring FGFR2-AHCYL1 demonstrated stable disease when treated with Derazantinib (ARQ 087) (PMID: 30420614; NCT01752920). | 30420614 |
FGFR2 - AHCYL1 | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-AHCYL1 were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - AHCYL1 | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pemazyre (pemigatinib) treatment decreased viability of transformed cells expressing FGFR2-AHCYL1 in culture (PMID: 35176488). | 35176488 |
FGFR2 - AHCYL1 | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-AHCYL1 were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - AHCYL1 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical | Actionable | In a preclinical study, treatment with Truseltiq (infigratinib) prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810). | 24122810 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|